Alkermes (ALKS)
(Delayed Data from NSDQ)
$27.37 USD
+0.78 (2.93%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $27.36 -0.01 (-0.04%) 5:18 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.37 USD
+0.78 (2.93%)
Updated Oct 10, 2024 04:00 PM ET
After-Market: $27.36 -0.01 (-0.04%) 5:18 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Alkermes (ALKS) concluded the recent trading session at $27.18, signifying a -1.74% move from its prior day's close.
Alkermes (ALKS) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
Alkermes (ALKS) closed the most recent trading day at $29.60, moving -0.84% from the previous trading session.
Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Alkermes (ALKS) closed the most recent trading day at $28.85, moving -1.16% from the previous trading session.
Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes (ALKS) Grants Teva License to Market Generic Drug
by Zacks Equity Research
Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. The stock of the company rises 7%.
Why Is Alkermes (ALKS) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows
by Zacks Equity Research
Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised
by Zacks Equity Research
Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
by Zacks Equity Research
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
by Zacks Equity Research
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
by Zacks Equity Research
Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.
Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 14.58% and 7.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.
Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y
by Zacks Equity Research
Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.